

Hanna Fredholm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3418571/publications.pdf>

Version: 2024-02-01

9
papers

555
citations

1478505

6
h-index

1720034

7
g-index

9
all docs

9
docs citations

9
times ranked

1022
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment. PLoS ONE, 2009, 4, e7695.	2.5	371
2	Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Research and Treatment, 2016, 160, 131-143.	2.5	82
3	Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer. JAMA Oncology, 2021, 7, 1360.	7.1	30
4	Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma. Cancer, 2000, 88, 2661-2667.	4.1	29
5	Breast cancer in young women and prognosis: How important are proliferation markers?. European Journal of Cancer, 2017, 84, 278-289.	2.8	24
6	Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?. Journal of Clinical Oncology, 2019, 37, 501-501.	1.6	17
7	Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.. Journal of Clinical Oncology, 2019, 37, 583-583.	1.6	2
8	One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.. Journal of Clinical Oncology, 2020, 38, 590-590.	1.6	0
9	Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.. Journal of Clinical Oncology, 2022, 40, 593-593.	1.6	0